CorMedix Inc. (CRMD) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CRMD scores 62 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

• Fundamental Cash Engine: 16 / 20. The pillar cites ROIC of 45.5% and an FCF yield of 0%. The strong return on invested capital is the main support; the zero FCF yield in the market data means the current share price does not reflect a cash return to holders on that basis.
• Whale / 13F Flow: 7 / 20. Institutional accumulation and options positioning are weak in this pillar. Holder-level detail is not provided in the source data, so the reasons for the low score cannot be traced further.
• Insider Conviction: 15 / 20. The pillar references SEC Form 4 and Congressional PTR cluster flow. Specific transactions are not itemized in the source data.
• Macro Regime Fit: 10 / 20. Beta is 1.0 and the pillar notes sector sensitivity. The stock is therefore not characterized as a low-beta defensive holding.
• Forensic Balance Sheet: 14 / 20. Altman Z-Score 1.81, Piotroski F-Score 8/9, Debt/Equity 0.5. The Piotroski reading is strong; the Altman reading sits in a range that warrants monitoring.

For a prospective investor, the rating describes a mixed profile: high reported profitability and a strong internal scoring of the balance sheet, offset by weak institutional flow, a zero FCF yield in the market data, and a macro/sector sensitivity score that is only mid-range. The share price has recently moved to a 52-week low, so the valuation multiples (P/E TTM 3.7, EV/EBITDA 3) should be read alongside the news flow below, which flags reimbursement risk. The upside case rests on sustained margin and return metrics; the downside case rests on the revenue concentration and reimbursement exposure implied by the news wire, which the source data does not quantify.

CorMedix Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The profile identifies the company by sector, industry, exchange, and market capitalization of $0.6B. Gross margin is reported at 88.5%, operating margin at 48.2%, and net margin at 52.3%. The recent news wire references the DefenCath and Rezzayo products and their reimbursement and FDA review status; product-level revenue split and customer detail are not provided in the source data.

• RISK WATCH (RED): A Yahoo Finance item reports a fresh 52-week low tied to DaVita's warning of a sharp 2027 DefenCath reimbursement drop.
• CATALYST (GREEN): A kalkine.ca item describes a commercial growth narrative for the company.
• CATALYST (GREEN): A Simply Wall St item discusses EPS growth as a basis for the stock's case.
• MARKET WIRE (YELLOW): A Seeking Alpha item reports a Rezzayo label expansion under FDA review.
• MARKET WIRE (YELLOW): A MarketBeat item reports the stock reaching a new 1-year low.
• MARKET WIRE (YELLOW): A Yahoo Finance comparison item covers CRMD against PRTA on value grounds.

The news wire is mixed: one red risk item on 2027 reimbursement, two green catalysts, and three yellow market-wire items. The Butterfly Supply-Chain Graph contains no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The one ripple the news wire does point to is reimbursement: the DaVita warning on 2027 DefenCath reimbursement implies that payer-side pricing decisions could transmit into the company's revenue, and an investor should monitor reimbursement announcements as the primary second-order channel.

• What share of FY 2025 revenue is attributable to DefenCath versus other products, and how large is the 2027 reimbursement reduction referenced in the news wire?
• What is the FY 2025 debt balance and the EPS figure for each reported period, given both are listed as N/A in the financials?
• Why does the Roarable RQD rating assign a zero FCF yield in market data when FY 2025 reported FCF is $172.8M?
• What are the 13F holder changes and Form 4 insider transactions behind the Whale and Insider pillar scores?
• What is the status and expected timing of the Rezzayo label expansion under FDA review?